Baiji Shenzhou published lifirafenib in conjunction with Mirdametinib preclinical data.

Researchers from The Encyclopedia, SpringWorks, and Memorial Sloan-Kettering Cancer Center released preclinical data in the form of posters at the American Cancer Research Association's (AACR) 2020 Annual Meeting IIThe results showed that lifirafenib combined with mirdametinib at clinically related compound concentrations showed high activity and synergy effects in a series of tumor models carrying RAS mutations in the body and in vitroIn addition, this combination of drugs demonstrated good synergies in kraS Q61K and KRAS G12C heterotransplant models, which were confirmed by drug-effect signaling pathway suppression and tumor subsidyThese preclinical results further support the ongoing phase 1b/2 joint drug trial to evaluate the strategic treatment of pathways that carry RAS mutations and other MAPK signaling pathwaysbased on the progress of the project and the clinical data observed to date, the two companies reaffirmed their previously proposed pilot plan to confirm that the dose-incremental portion of the trial will be completed by 2020 and that a dose-extended trial group will be initiated in specific tumor categories, which will include non-small cell lung cancer with KRAS mutations and uterine cancer with KRAS mutationsPreliminary clinical data on the trial are expected to be released at a medical conference in 2021.